• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组组织型纤溶酶原激活剂与尿激酶联合输注用于急性心肌梗死患者的冠状动脉溶栓治疗。

Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.

作者信息

Topol E J, Califf R M, George B S, Kereiakes D J, Rothbaum D, Candela R J, Abbotsmith C W, Pinkerton C A, Stump D C, Collen D

机构信息

Department of Internal Medicine, University of Michigan, Ann Arbor.

出版信息

Circulation. 1988 May;77(5):1100-7. doi: 10.1161/01.cir.77.5.1100.

DOI:10.1161/01.cir.77.5.1100
PMID:2966017
Abstract

To determine whether tissue-type plasminogen activator (t-PA) and urokinase (UK) act synergistically to achieve coronary thrombolysis, incremental doses of both drugs were infused intravenously over 60 min. In 146 consecutive patients treated 3.0 +/- 1.0 hr from symptom onset, coronary angiography was performed 90 min after the start of the infusion and at 7 days. The groups of patients treated by different dose regimen were as follows: group I, 14 patients treated with t-PA 25 mg and UK 0.5 million U; group II, 20 patients given t-PA 25 mg and UK 1.0 million U; group III, 24 patients given t-PA 1.0 mg/kg and UK 0.5 million U; group IV, 33 patients treated with t-PA 1.0 mg/kg and UK 1.0 million U; and group V, 55 patients given t-PA 1.0 mg/kg and UK 2.0 million U. In groups I and II, patency of the infarct-related vessel at 90 min was only 36% and 42%, respectively. With 1 mg/kg t-PA and increasing doses of UK (groups III to V), patency ranged from 72% to 75% (overall 73%). Repeat catheterization at 7 days demonstrated reocclusion in groups III to V in 10 of 110 (9%). The patency and reocclusion rates in groups III to V were not significantly different from those in our previous study of 386 patients treated with t-PA alone (150 mg over 6 to 8 hr). In that study the patency rate of the infarct-related vessel at 90 min was 75% (p = .66) and reocclusion occurred in 15% (p = .11).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为确定组织型纤溶酶原激活剂(t-PA)与尿激酶(UK)是否协同作用以实现冠状动脉溶栓,两种药物的递增剂量在60分钟内静脉输注。在症状发作后3.0±1.0小时接受治疗的146例连续患者中,输注开始90分钟后及7天时进行冠状动脉造影。不同剂量方案治疗的患者组如下:I组,14例患者接受25毫克t-PA和50万单位UK治疗;II组,20例患者给予25毫克t-PA和100万单位UK;III组,24例患者给予1.0毫克/千克t-PA和50万单位UK;IV组,33例患者接受1.0毫克/千克t-PA和100万单位UK治疗;V组,55例患者给予1.0毫克/千克t-PA和200万单位UK。在I组和II组中,90分钟时梗死相关血管的通畅率分别仅为36%和42%。使用1毫克/千克t-PA和递增剂量的UK(III组至V组),通畅率在72%至75%之间(总体为73%)。7天时重复导管插入术显示,III组至V组中110例中有10例(9%)再次闭塞。III组至V组的通畅率和再闭塞率与我们之前对386例单独接受t-PA治疗(6至8小时内给予150毫克)患者的研究结果无显著差异。在该研究中,90分钟时梗死相关血管的通畅率为75%(p = 0.66),再闭塞发生率为15%(p = 0.11)。(摘要截取自250字)

相似文献

1
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.重组组织型纤溶酶原激活剂与尿激酶联合输注用于急性心肌梗死患者的冠状动脉溶栓治疗。
Circulation. 1988 May;77(5):1100-7. doi: 10.1161/01.cir.77.5.1100.
2
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.单链尿激酶型纤溶酶原激活剂与重组组织型纤溶酶原激活剂低剂量协同组合的凝块选择性冠状动脉溶栓治疗。心肌梗死尿激酶原研究组。
Am J Cardiol. 1991 Dec 15;68(17):1564-9. doi: 10.1016/0002-9149(91)90310-h.
3
A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
J Am Coll Cardiol. 1989 Sep;14(3):573-80. doi: 10.1016/0735-1097(89)90095-8.
4
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.用于冠状动脉溶栓的加速纤溶酶原激活剂给药方案。TAMI - 7研究组。
J Am Coll Cardiol. 1992 Mar 1;19(3):482-9. doi: 10.1016/s0735-1097(10)80259-1.
5
[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Klin Wochenschr. 1988;66 Suppl 12:102-8.
6
Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.联合溶栓治疗:组织纤溶酶原激活剂与尿激酶同步和序贯方案的比较
Am Heart J. 1991 Aug;122(2):375-80. doi: 10.1016/0002-8703(91)90988-t.
7
Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.重组组织型纤溶酶原激活剂单次大剂量给药:对血栓闭塞/再灌注犬模型中梗死相关血管通畅、微血管灌注和微血管再闭塞的影响
Cardiovasc Res. 1991 Mar;25(3):184-91. doi: 10.1093/cvr/25.3.184.
8
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.静脉注射组织型纤溶酶原激活剂再灌注治疗失败患者的特征及预后:心肌梗死溶栓与血管成形术(TAMI)I试验结果
Circulation. 1988 May;77(5):1090-9. doi: 10.1161/01.cir.77.5.1090.
9
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).急性心肌梗死中静脉注射重组组织型纤溶酶原激活剂(rt-PA)与尿激酶:德国激活剂尿激酶研究(GAUS)结果
J Am Coll Cardiol. 1988 Sep;12(3):581-7. doi: 10.1016/s0735-1097(88)80040-8.
10
Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.急性心肌梗死中突变型组织型纤溶酶原激活剂与尿激酶的血管造影研究。
Jpn Circ J. 1998 Feb;62(2):111-4. doi: 10.1253/jcj.62.111.

引用本文的文献

1
Changes of fibrinolytic system in thrombolytic resuscitation of pulmonary thromboembolism-induced cardiac arrest model.溶栓复苏肺血栓栓塞症致心跳骤停模型中纤溶系统的变化。
Int Wound J. 2021 Dec;18(6):874-880. doi: 10.1111/iwj.13589. Epub 2021 May 4.
2
Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.对于超急性大脑中动脉缺血性卒中患者,在早期静脉注射组织型纤溶酶原激活剂治疗无效后,进行挽救性局部动脉内溶栓治疗。
Neuroradiology. 2005 Aug;47(8):616-21. doi: 10.1007/s00234-005-1388-2. Epub 2005 Jun 28.
3
Indications for thrombolytic therapy in acute pulmonary embolism.
急性肺栓塞溶栓治疗的适应证
Tex Heart Inst J. 1989;16(1):19-26.
4
After thrombolytic therapy: angiography, angioplasty, or surgery?溶栓治疗后:血管造影、血管成形术还是手术?
Tex Heart Inst J. 1990;17(3):165-72.
5
Rescue PTCA Following Failed Thrombolysis and Primary PTCA: A Retrospective Study of Angiographic and Clinical Outcome.溶栓失败后补救性经皮冠状动脉腔内血管成形术及直接经皮冠状动脉腔内血管成形术:血管造影及临床结果的回顾性研究
J Thromb Thrombolysis. 1997;4(2):281-288. doi: 10.1023/a:1008807321037.
6
A Simple, Reproducible Animal Model of Arterial Occlusion with Mixed Thrombus.
J Thromb Thrombolysis. 1996;3(4):337-341. doi: 10.1007/BF00133077.
7
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.糖蛋白IIb/IIIa抑制剂联合纤溶治疗在急性心肌梗死中的应用。
J Thromb Thrombolysis. 1999 Jun;7(3):241-5. doi: 10.1023/a:1008974909124.
8
Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion.
J Nucl Cardiol. 1994 Mar-Apr;1(2 Pt 1):124-37. doi: 10.1007/BF02984084.
9
Implications of the GUSTO trial for thrombolytic therapy.GUSTO试验对溶栓治疗的启示。
Drugs. 1996 Sep;52(3):307-12. doi: 10.2165/00003495-199652030-00001.
10
Construction of a literature database and its use to provide probabilities for decision-analytic models of thrombolytic therapy.构建文献数据库及其用于为溶栓治疗的决策分析模型提供概率。
Proc Annu Symp Comput Appl Med Care. 1994:819-23.